Edesa Biotech (EDSA) to Release Earnings on Tuesday

05 May 2026, 13:50 by Renee Jackson · The Cerbat Gem

Edesa Biotech (NASDAQ:EDSA – Get Free Report) will likely be posting its results before the market opens on Tuesday, May 12th. Analysts expect Edesa Biotech to post earnings of ($0.24) per share for the quarter.

Edesa Biotech (NASDAQ:EDSA – Get Free Report) last issued its earnings results on Friday, February 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.28). The company had revenue of $0.11 million during the quarter. On average, analysts expect Edesa Biotech to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Edesa Biotech Stock Down 3.0%

Shares of Edesa Biotech stock traded down $0.48 during mid-day trading on Tuesday, hitting $15.63. The stock had a trading volume of 194,801 shares, compared to its average volume of 3,386,635. The firm has a 50-day moving average of $6.20 and a two-hundred day moving average of $3.23. Edesa Biotech has a 12-month low of $0.72 and a 12-month high of $20.32. The firm has a market cap of $138.90 million, a P/E ratio of -13.59 and a beta of 1.26.

Insiders Place Their Bets

In related news, CEO Pardeep Nijhawan bought 10,000 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The stock was purchased at an average price of $3.90 per share, for a total transaction of $39,000.00. Following the acquisition, the chief executive officer owned 402,702 shares of the company’s stock, valued at approximately $1,570,537.80. This trade represents a 2.55% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. In the last three months, insiders have purchased 73,571 shares of company stock valued at $184,142. 24.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Edesa Biotech

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. DRW Securities LLC purchased a new position in Edesa Biotech during the 4th quarter valued at about $191,000. Diadema Partners LP purchased a new position in Edesa Biotech in the 4th quarter valued at approximately $77,000. State Street Corp purchased a new position in Edesa Biotech in the 4th quarter valued at approximately $27,000. Finally, Susquehanna International Group LLP purchased a new position in Edesa Biotech in the 3rd quarter valued at approximately $36,000. 5.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on EDSA. Weiss Ratings reissued a “sell (e+)” rating on shares of Edesa Biotech in a research note on Friday, March 27th. Wall Street Zen upgraded Edesa Biotech from a “sell” rating to a “hold” rating in a report on Sunday, April 5th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $5.00.

Read Our Latest Stock Report on Edesa Biotech

Edesa Biotech Company Profile

(Get Free Report)

Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.